EU regulators approve AstraZeneca's Lynparza in pancreatic c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation. 

NICE rejects MSD/Pfizer's combination in untreated kidney ca...

NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) in untreated kidney cancer, citing uncertainties about its lon

NICE backs Lynparza across the board for BRCA+ovarian cancer

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.

MSD’s Keytruda plus chemo backed by NICE for lung cancer

AZ/MSD’s Lynparza sees positive results in prostate cancer

AstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).